Laura Joszt, MA

Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).

Direct inpatient and outpatient costs are significantly higher for patients with untreated spinal muscular atrophy (SMA) compared with matched controls.

Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.

While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.

While only 3 small interfering RNA (siRNA)-based therapies have been approved, the market is poised to expand with 7 other candidates in phase 3 trials.

The FDA has granted priority review of the supplemental New Drug Application for ruxolitinib for the treatment of steroid-refractory chronic graft-versus host disease (GVHD).

Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.

In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.

The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.

Coverage of the National Association of Accountable Care Organizations (ACOs) fall meeting.

In the real world, the persistence rate with secukinumab to treat psoriatic arthritis was higher than with ustekinumab.

Updated guidance in 6 key areas of asthma care focus on improving diagnosis, management, and treatment.

Combination therapy plays a central role in treating pulmonary arterial hypertension (PAH), and 2 abstracts presented at the CHEST annual meeting highlighted real-world treatment patterns.

Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.

While death rates related to HIV infection declined from 2010 to 2017, differences in HIV-related deaths remain among certain populations.

The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.

The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.

At its annual meeting, the American College of Rheumatology previewed updates to guidelines for the management of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).

Severe pulmonary arterial hypertension (PAH) was associated with a significantly higher rate of maternal and fetal mortality.

Expansion of insurance coverage due to the Affordable Care Act led to a reduction in the use of emergency services for patients with asthma in New York City.

Although half of US rheumatologists have patients for which nonmedical switching has been suggested, only 35% were likely to switch patients with rheumatoid arthritis doing well on a reference product to a biosimilar.

Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.

A multidisciplinary spine intervention can reduce chronic back pain–related health care utilization and costs, according to a study published in Spine.

Improvements in completed visits while using telemedicine to conduct rheumatology visits during the coronavirus disease 2019 pandemic may present an option for continued telemedicine use for follow-up care.

Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.

Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.

Despite concerns about treatment with immunosuppressive agents, coronavirus disease 2019 (COVID-19) infection remains low in patients with rheumatic diseases, according to 2 abstracts presented at the annual meeting of the American College of Rheumatology.

As novel therapies drive up the cost of cancer care, federal policy decisions are being made that influence oncologists' ability to deliver cancer care, said Debra Patt, MD, PhD, MBA, MPH, of Texas Oncology.

The Trump administration finalized rules aimed at making health care pricing more visible and transparent to those with with health insurance from employers or the individual market.